Clinical trials
Recurrent Cancer clinical trials
Below are recruiting recurrent cancer clinical trials, each written for real people, not researchers. We’re tracking 678 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04288999RecruitingPhase 3
Surgery plus chemo versus chemo-radiation then surgery for recurrent rectal cancer
This study compares two treatment plans for locally recurrent rectal cancer: (1) surgery plus chemo, or (2) chemo plus radiation first, then surgery, followed by chemo. It aims to see which approach works better in controlling the cancer and helping patients recover.
ChibaAges 20–80 - NCT04389086RecruitingPhase 3
Chemotherapy before surgery for recurring rectal cancer
This trial tests an “induction chemotherapy” treatment before surgery for people whose rectal cancer has come back in the local area. The goal is to shrink/control the cancer early and improve outcomes after treatment.
GhentAges 18 years+ - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT07714668RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07667192Recruiting
Re-treating gynecologic cancer with repeat radiation or ablation
This trial studies using additional radiation or tumor-destroying techniques for gynecologic cancer that has come back after previous radiation treatment. It helps doctors understand if this approach is safe and effective for women with recurrent disease.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT06780748RecruitingPhase 2
Light-guided re-surgery for recurrent breast cancer
This trial uses a special light and dye to help surgeons find and remove lymph nodes that might contain cancer cells, in women whose breast cancer has come back in the same area after previous surgery.
Goyang-siAges 18 years+ - NCT07443475RecruitingPhase 2
Electric field therapy for vulvar cancer that has come back
This trial tests whether a targeted electric current can improve treatment for vulvar cancer that has returned after standard therapy. The treatment uses electricity to help chemotherapy drugs enter cancer cells more effectively.
LjubljanaAges 18 years+ - NCT07365423RecruitingPhase 2
Terbinafine for prostate cancer with rising PSA
This trial tests if the antifungal drug terbinafine can lower PSA levels in men whose prostate cancer has returned after standard treatments, but who are not yet ready for hormone therapy. It is for men with no distant spread seen on scans except possibly small lymph nodes.
BadenAges 18 years+ - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT07234656Recruiting
Study on fear of cancer returning in kidney cancer
This study looks at fear of cancer recurrence in people with kidney cancer and their partners. It aims to understand and help manage these fears. You and your partner may join if you had surgery for early-stage kidney cancer.
AalborgAges Any age - NCT07030686Recruiting
Exercise and quality of life in cancer survivors
This study looks at how exercise habits are linked to how cancer survivors feel and their health outcomes. It may help understand if starting to exercise improves well-being.
Los Angeles, CaliforniaAges 18 years+ - NCT06964009RecruitingPhase 1
New drug plus paclitaxel for resistant ovarian cancer
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
Boston, MassachusettsAges 18 years+ - NCT06873763RecruitingPhase 1/Phase 2
Nelmastobart with chemo for advanced colorectal cancer
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06771193Recruiting
Study of cervical cancer treatment patterns in Italy
This study looks at the types of treatments and disease characteristics in people with cervical cancer that is locally advanced (cannot be removed by surgery) or has come back or spread. It may help doctors understand how different treatments are used in Italy.
Bologna, BolognaAges 18 years+ - NCT06781151Recruiting
Personalized treatment for recurrent gynecologic cancers
This study tests if personalized treatment plans, based on detailed genetic testing of your tumor, can help women with recurrent ovarian, cervical, or endometrial cancer. You will work with a team of specialists to find the best options for you.
Guangzhou, GuangdongAges 18 years+ - NCT06366490RecruitingPhase 1
Personalized vaccine for recurrent ovarian cancer
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06321484RecruitingPhase 1
NK cell therapy for recurrent platinum-resistant ovarian cancer
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
Boston, MassachusettsAges 18–85 - NCT06314958Recruiting
Follow-up after colorectal cancer treatment
This study follows people who have finished treatment for stage II (high-risk) or stage III colorectal cancer and are now cancer-free. Researchers want to learn more about which factors might predict if the cancer will come back, so they can better personalize follow-up care.
Monrovia, CaliforniaAges 18 years+ - NCT06181331Recruiting
Managing fear of cancer recurrence with a step-by-step program
This trial tests a program to help Chinese-speaking cancer survivors manage their fear of cancer coming back. You may join if you have worries about recurrence but at a level that is not severe.
Hong KongAges 18 years+ - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Little Rock, ArkansasAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Gilbert, ArizonaAges 18 years+ - NCT05632913Recruiting
Radiation seeds trial for recurring lung cancer in the chest
This trial tests a treatment that places tiny radiation “seeds” inside/near the chest tumor to treat recurrent lung cancer. It may help people whose cancer has come back and can be safely reached by the radiation device.
JerusalemAges 18 years+
Hear when a new Recurrent Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent cancer?
- Yes. Clin2 currently lists 678 recruiting recurrent cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.